Macrophages polarization in renal inflammation and fibrosis animal models (Review)

Mol Med Rep. 2024 Feb;29(2):29. doi: 10.3892/mmr.2023.13152. Epub 2023 Dec 22.

Abstract

Chronic kidney disease (CKD) is a significant public health concern. Renal fibrosis is the final common pathway in the progression of kidney diseases, irrespective of the initial injury. Substantial evidence underscores the pivotal role of renal inflammation in the genesis of renal fibrosis. The presence of macrophages within normal renal tissue is significantly increased within diseased renal tissue, indicative of their crucial regulatory function in inflammation and fibrosis. Macrophages manifest a high degree of heterogeneity, exhibiting distinct phenotypic and functional traits in response to diverse stimuli within the local microenvironment in various types of kidney diseases. Broadly, macrophages are categorized into two principal groups: Classically activated, designated as M1 macrophages and alternatively activated, designated as M2 macrophages. A number of experimental models are widely used to study the underlying mechanisms driving renal inflammation and fibrosis progression. The present review delineated the phenotypic and functional attributes of macrophages present in diverse induced models, analyzing their disposition in relation to M1 and M2 polarization states.

Keywords: kidney disease; macrophage polarization; macrophages; renal inflammation and fibrosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Fibrosis
  • Inflammation / metabolism
  • Macrophages / metabolism
  • Nephritis* / metabolism
  • Renal Insufficiency, Chronic* / metabolism

Grants and funding

The present study was supported by funding from the Natural Science Foundation of Anhui Province (grant no 2008085MH273), the Anhui Fund for Distinguished Young Scholars (grant no. 2022AH020050), the Scientific Research Platform Improvement Project of Anhui Medical University (grant no. 2022×kjT045) and the Research Fund of Anhui Institute of translational medicine (grant no. 2021zhyx-B06 and 2022zhyx-B07).